Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | LSS | P48449 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252023 | 0.86 | MEN1 (0.57) | KMT2AMEN1ATML3MBTL1HTT | |
| SCHEMBL10975241 | 0.86 | KMT2A (0.68) | KMT2AMEN1ATML3MBTL1HTT | |
| SCHEMBL10974483 | 0.84 | L3MBTL1 (0.68) | KMT2AMEN1L3MBTL1HTTPOLB | |
| SCHEMBL2377868 | 0.84 | ALDH1A1 (0.65) | SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL19264944 | 0.84 | GAA (0.52) | KMT2AMEN1L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL23775640 | 0.84 | KMT2A (0.66) | KMT2AMEN1ATML3MBTL1HTT | |
| SCHEMBL10979638 | 0.84 | POLB (0.62) | KMT2AMEN1LMNAPOLBALDH1A1 | |
| SCHEMBL5254470 | 0.84 | LMNA (0.53) | KMT2AMEN1ATML3MBTL1HTT | |
| SCHEMBL21894630 | 0.84 | ALDH1A1 (0.57) | KMT2AMEN1ATMHTTSMN1; SMN2 | |
| SCHEMBL4580893 | 0.83 | ATM (0.81) | KMT2AMEN1ATML3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| EP-0060610-B1 | HEXAHYDRO-TRANS- AND TETRAHYDROPYRIDOINDOLE NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| US-4432978-A | NEUROLEPTIC AGENTS, TRANQUILIZERS | PFIZER INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4431649-A | TRANQUILIZERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4431646-A | TRANQUILIZERS; PSYCHOSIS; NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4427679-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | PFIZER INC. (US) | 1984-01-24 | — | — | US | disclosed |
| EP-0060610-A1 | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | PFIZER INC. (US) | 1982-09-22 | — | — | EP | disclosed |
| US-4337250-A | NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1982-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | KMT2A 3354/4885MEN1 2423/4885ATM 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.